Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q24647905)
Watch
English
Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
author
Enriqueta Felip
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
author name string
Rafael Rosell
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
language of work or name
English
0 references
publication date
1 June 2008
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
published in
Therapeutics and Clinical Risk Management
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
volume
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
issue
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
page(s)
579-585
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
copyright license
Creative Commons Attribution-NonCommercial 3.0 Unported
start time
1 June 2008
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
7 April 2017
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
The promise of pharmacogenomics: gemcitabine and pemetrexed.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Pemetrexed in previously treated non-small-cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 September 2017
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 November 2018
Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 November 2018
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 November 2018
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2500250
retrieved
28 November 2018
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18827853
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18827853
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Single-Institution Experience with Pemetrexedand Bevacizumab as Salvage Therapy in AdvancedNon–Small-Cell Lung Cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18827853
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18827853
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.2147/TCRM.S2248
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
PMC publication ID
2500250
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
PubMed publication ID
18827853
1 reference
stated in
Europe PubMed Central
PMC publication ID
2500250
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18827853%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit